International Urology and Nephrology

, Volume 39, Issue 3, pp 879–886 | Cite as

A prospective study of the efficacy of Serenoa repens, Tamsulosin, and Serenoa repens plus Tamsulosin treatment for patients with benign prostate hyperplasia

  • Fatih HızlıEmail author
  • M. Cemil Uygur
Original Paper



Increasing attention has been focused on the use of phytotherapeutic agents to alleviate the symptoms of benign prostatic hyperplasia (BPH) in recent times. The best described and studied phytotherapeutic agent is Serenoa repens (SR).

Materials and methods

This prospective study was designed to have 3 arms including SR 320 mg per day (N = 20), Tamsulosin (TAM) 0.4 mg per day (N = 20) and SR + TAM (N = 20) to reveal the superiority or equivalence between these treatment regimens in BPH.


The groups were not statistically different with regard to increase in maximal urinary flow rate (Q max) and decrease in International Prostate Symptom Score (I-PSS) (P > 0.05). No adverse effect was detected in SR therapy group.


Treatment of BPH by both SR and TAM seems to be effective alone. None of them had superiority to another and additionally, combined therapy (SR + TAM) does not provide extra benefits. Furthermore SR is a well-tolerated agent that can be used alternatively in the treatment of LUTS due to BPH.


Serenoa repens BPH Tamsulosin Treatment 


  1. 1.
    Holtgrewe HL (1998) Current trends in management of men with lower urinary tract symptoms and benign prostatic hyperplasia. Urology 51(Suppl 4A):1–7PubMedCrossRefGoogle Scholar
  2. 2.
    Oesterling JE (1995) Benign prostatic hyperplasia. Medical and minimally invasive treatment options. N Engl J Med 332:99–109PubMedCrossRefGoogle Scholar
  3. 3.
    Buck AC (1996) Phytotheraphy for the prostate. Br J Urol 78:325–336PubMedGoogle Scholar
  4. 4.
    Wilt TJ, Ishani A, Stark G et al (1998) Saw palmetto extracts for treatment of benign prostatic hyperplasia: a systematic review. JAMA 280(18):1604–1609PubMedCrossRefGoogle Scholar
  5. 5.
    Lowe FC, Fagelman E (1999) Phytotheraphy in the treatment of benign prostatic hyperplasia: an update. Urology 53(4):671–678PubMedCrossRefGoogle Scholar
  6. 6.
    Chacon A, Monga M (1999) Medical management of benign prostatic hyperplasia. Geriatr Nephrol Urol 9(1):39–48PubMedCrossRefGoogle Scholar
  7. 7.
    Clifford GM, Farmer RD (2000) Medical therapy for benign prostatic hyperplasia. A review of the literature. Eur Urol 38(1):2–19PubMedCrossRefGoogle Scholar
  8. 8.
    Champault G, Patel JC, Bonnard AM (1984) A double-blind trial of an extract of the plant Serenoa Repens in benign prostatic hypertrophy. Br J Clin Pharmacol 18(3):461–462PubMedGoogle Scholar
  9. 9.
    Tasca A, Barulli M, Cavazzana A et al (1985) Treatment of obstructive symptomatology caused by prostatic adenoma with an extract of Serenoa repens. Double-blind clinical study vs. placebo. Minerva Urol Nefrol 37(1):87–91PubMedGoogle Scholar
  10. 10.
    Cukier J, Ducassou J, Le Guillou M et al (1985) Permixon versus placebo: results of a multicentre study. C R Ther Pharmacol Clin 4:15–21Google Scholar
  11. 11.
    Descotes JL, Rambeaud JJ, Deschaseaux P et al (1995) Placebo-controlled evaluation of the efficacy and tolerability of Permixon in benign prostatic hyperplasia after exclusion of placebo responders. Clin Drug Invest 9:291–297Google Scholar
  12. 12.
    Carraro JC, Raynaud JP, Koch G et al (1996) Comparison of phytotheraphy (Permixon) with finasteride in the treatment of benign prostate hyperplasia: a randomized international study of 1098 patients. Prostate 29(4):231–240PubMedCrossRefGoogle Scholar
  13. 13.
    Debruyne F, Koch G, Boyle P et al (2002) for the members of the PERMAL Study Comparison of a phytotherapeutic agent (Permixon) with an α-blocker(tamsulosin) in the treatment of benign prostatic hyperplasia: a 1-year randomized international study. Eur Urol 41:497–507PubMedCrossRefGoogle Scholar
  14. 14.
    Neal DE (1997) Watchful waiting or drug therapy for benign prostatic hyperplasia? Lancet 350:305–306PubMedCrossRefGoogle Scholar
  15. 15.
    Boyle P, Gould AL, Roehrborn CG (1996) Prostate volume predicts outcome of treatment of benign prostatic hyperplasia with finasteride: meta-analysis of randomized clinical trials. Urology 48:398–405PubMedCrossRefGoogle Scholar
  16. 16.
    Di Salle E, Briatico G, Giudici D et al (1994) Novel aromatase and 5 alpha-reductase inhibitors. J Steroid Biochem Mol Biol 49:289–294PubMedCrossRefGoogle Scholar
  17. 17.
    Di Salle E, Briatico G, Giudici D et al (1994) Endocrine properties of the testosterone 5 alpha-reductase inhibitor turosteride (FCE 26073). J Steroid Biochem Mol Biol 48:241–248PubMedCrossRefGoogle Scholar
  18. 18.
    Jardin A, Bensadoun H, Delauche-Cavallier MC et al (1991) Alfuzosin for treatment of benign prostatic hypertrophy. The BPH-ALF Group. Lancet 337:1457–1461PubMedCrossRefGoogle Scholar
  19. 19.
    Abrams P (1997) Urodynamic effects of doxazosin in men with lower urinary tract symptoms and benign prostatic obstruction. Results from three double-blind placebo-controlled studies. Eur Urol 32:39–46PubMedGoogle Scholar
  20. 20.
    Astin JA (1998) Why patients use alternative medicine: results of a national study. JAMA 279:1548–1553PubMedCrossRefGoogle Scholar
  21. 21.
    Vincent C, Furnham A (1996) Why do patients turn to complementary medicine? An empirical study. Br J Clin Psychol 35(Pt 1):37–48PubMedGoogle Scholar
  22. 22.
    Furnham A, Forey J (1994) The attitudes, behaviors and beliefs of patients of conventional vs. complementary (alternative) medicine. J Clin Psychol 50(3):458–469PubMedCrossRefGoogle Scholar
  23. 23.
    Weisser H, Tunn S, Behnke B, Krieg M (1996) Effects of the sabal serrulata extract IDS 89 and its subfractions on 5 alpha-reductase activity in human benign prostatic hyperplasia. Prostate 28(5):300–306PubMedCrossRefGoogle Scholar
  24. 24.
    Iehle C, Delos S, Guirou O, Tate R, Raynaud JP, Martin PM (1995) Human prostatic steroid 5 alpha-reductase isoforms – a comparative study of selective inhibitors. J Steroid Biochem Mol Biol 54(5–6):273–279PubMedCrossRefGoogle Scholar
  25. 25.
    Plosker GL, Brogden RN (1996) Serenoa repens (Permixon). A review of its pharmacology and therapeutic efficacy in benign prostatic hyperplasia. Drugs Aging 9(5):379–395PubMedCrossRefGoogle Scholar
  26. 26.
    Sultan C, Terraza A, Devillier C, Carilla E, Briley M, Loire C, Descomps B (1984) Inhibition of androgen metabolism and binding by a liposterolic extract of “Serenoa repens B” in human foreskin fibroblasts. J Steroid Biochem 20(1):515–519PubMedCrossRefGoogle Scholar
  27. 27.
    Carilla E, Briley M, Fauran F, Sultan C, Duvilliers C (1984) Binding of Permixon, a new treatment for prostatic benign hyperplasia, to the cytosolic androgen receptor in the rat prostate. J Steroid Biochem 20(1):521–523PubMedCrossRefGoogle Scholar
  28. 28.
    Ravenna L, Di Silverio F, Russo MA, Salvatori L, Morgante E, Morrone S, Cardillo MR, Russo A, Frati L, Gulino A, Petrangeli E (1996) Effects of the lipidosterolic extract of Serenoa repens (Permixon) on human prostatic cell lines. Prostate 29(4):219–230PubMedCrossRefGoogle Scholar
  29. 29.
    Paubert-Braquet M, Mencia Huerta JM, Cousse H, Braquet P (1997) Effect of the lipidic lipidosterolic extract of Serenoa repens (Permixon) on the ionophore A23187-stimulated production of leukotriene B4 (LTB4) from human polymorphonuclear neutrophils. Prostaglandins Leukot Essent Fatty Acids 57(3):299–304PubMedCrossRefGoogle Scholar
  30. 30.
    Debruyne F, Boyle P, Calais Da Silva F, Gillenwater JG, Hamdy FC, Perrin P, Teillac P, Vela-Navarrete R, Raynaud JP, Schulman CC (2004) Evaluation of the clinical benefit of permixon and tamsulosin in severe BPH patients-PERMAL study subset analysis. Eur Urol 45(6):773–779PubMedCrossRefGoogle Scholar
  31. 31.
    Wilt TJ, Ishani A, Stark G, MacDonald R, Lau J, Mulrow C (1998) Saw palmetto extracts for treatment of benign prostatic hyperplasia: a systematic review. JAMA 280(18):1604–1609PubMedCrossRefGoogle Scholar
  32. 32.
    Glemain P, Coulange C, Billebaud T, Gattegno B, Muszynski R, Loeb G (2002) Groupe de l’essai OCOS [Tamsulosin with or without Serenoa repens in benign prostatic hyperplasia: the OCOS trial]. Prog Urol 12(3):395–403Google Scholar
  33. 33.
    Zlotta AR, Teillac P, Raynaud JP, Schulman CC (2005) Evaluation of male sexual function in patients with Lower Urinary Tract Symptoms (LUTS) associated with Benign Prostatic Hyperplasia (BPH) treated with a phytotherapeutic agent (Permixon), Tamsulosin or Finasteride. Eur Urol 48(2):269–276PubMedCrossRefGoogle Scholar
  34. 34.
    Braeckman J, Denis L, de Lavel J et al (1997) A double-blind, placebo-controlled study of the plant extract Serenoa repens in the treatment of benign hyperplasia of the prostate. Eur J Clin Res 9:247–259Google Scholar
  35. 35.
    Carbin BE, Larsson B, Lindahl O (1990) Treatment of benign prostatic hyperplasia with phytosterols. Br J Urol 66(6):639–641PubMedGoogle Scholar
  36. 36.
    Willetts KE, Clements MS, Champion S, Ehsman S, Eden JA (2003) Serenoa repens extract for benign prostate hyperplasia: a randomized controlled trial. BJU Int 92(3):267–270PubMedCrossRefGoogle Scholar
  37. 37.
    Gerber GS, Kuznetsov D, Johnson BC, Burstein JD (2001) Randomized, double-blind, placebo-controlled trial of saw palmetto in men with lower urinary tract symptoms. Urology 58(6):960–964PubMedCrossRefGoogle Scholar
  38. 38.
    Boyle P, Robertson C, Lowe F, Roehrborn C (2004) Updated meta-analysis of clinical trials of Serenoa repens extract in the treatment of symptomatic benign prostatic hyperplasia. BJU Int 93(6):751–756PubMedCrossRefGoogle Scholar
  39. 39.
    Bent S, Kane C, Shinohara K et al (2006) Saw Palmetto for benign prostatic hyperplasia. N Engl J Med 354:557–566PubMedCrossRefGoogle Scholar
  40. 40.
    Lepor H (1998) Long-term evaluation of tamsulosin in benign prostatic hyperplasia: placebo-controlled, double-blind extension of phase III trial. Tamsulosin Investigator Group. Urology 51(6):901–906PubMedCrossRefGoogle Scholar
  41. 41.
    Brooks SK (1999) Effect of tamsulosin on AUA symptom score and BPH impact index as a function of symptom severity in patients with benign prostatic hyperplasia. J Urol 161(Suppl):267CrossRefGoogle Scholar
  42. 42.
    Schulman CC, Cortvriend J, Jonas U, Lock TM, Vaage S, Speakman MJ (1999) Tamsulosin: 3-year long-term efficacy and safety in patients with lower urinary tract symptoms suggestive of benign prostatic obstruction: analysis of a European, multinational, multicenter, open-label study European Tamsulosin Study Group. Eur Urol 36(6):609–620PubMedCrossRefGoogle Scholar
  43. 43.
    Giannakopoulos X, Baltogiannis D, Giannakis D et al (2002) The lipidosterolic extract of Serenoa repens in the treatment of benign prostatic hyperplasia: a comparison of two dosage regimens. Adv Ther 19(6):285–296PubMedGoogle Scholar
  44. 44.
    Braeckman J (1994) The extract of Serenoa repens in the treatment of benign prostatic hyperplasia: a multicenter open study. Curr Ther Res 55:776–785CrossRefGoogle Scholar
  45. 45.
    Gerber GS, Zagaja GP, Bales GT, Chodak GW, Contreras BA (1998) Saw palmetto (Serenoa repens) in men with lower urinary tract symptoms: effects on urodynamic parameters and voiding symptoms. Urology 51(6):1003–1007PubMedCrossRefGoogle Scholar
  46. 46.
    Wang LG, Liu XM, Kreis W, Budman DR (1997) Down-regulation of prostate-specific antigen expression by finasteride through inhibition of complex formation between androgen receptor and steroid receptor-binding consensus in the promoter of the PSA gene in LNCaP cells. Cancer Res 57(4):714–719PubMedGoogle Scholar
  47. 47.
    Romics I, Schmitz H, Frang D (1993) Experience in treating benign prostatic hypertrophy with Sabal serrulata for one year. Int Urol Nephrol 25(6):565–569PubMedGoogle Scholar
  48. 48.
    Kondas J, Philipp V, Dioszeghy G (1996) Sabal serrulata extract (Strogen forte) in the treatment of symptomatic benign prostatic hyperplasia. Int Urol Nephrol 28(6):767–772PubMedCrossRefGoogle Scholar
  49. 49.
    Roveda S, Colombo P (1994) Sperimentazione clinica controllata sulla bioequivalenza terapeutica e sulla tollerabilita dei prodotti a base di Serenoa repens in capsule da 160 mg o capsule rettali da 640 mg. Arch Med Intern 46:61–75Google Scholar
  50. 50.
    Drew A (2000) An alternative stream: Serenoa repens for benign prostatic hypertrophy? Aust Prescr 23:79Google Scholar
  51. 51.
    Hamid S, Rojter S, Vierling J (1997) Protracted cholestatic hepatitis after the use of prostata. Ann Intern Med 127(2):169–170PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, Inc. 2006

Authors and Affiliations

  1. 1.Department of UrologyOncology Education and Research HospitalAnkaraTurkey
  2. 2.AnkaraTurkey

Personalised recommendations